Related Experiment Videos
[Alternatives to amniocentesis for maternal age]
F Audibert1, V Mairovitz, R Frydman
1Service de gynécologie-obstétrique, hôpital Antoine-Béclère, 157, rue de la Porte de Trivaux, 92140 Clamart, France. francois.audibert@abc.ap-hop-paris.fr
Gynecologie, Obstetrique & Fertilite
|August 30, 2002
Summary
Down's syndrome screening needs updating. Combining tests like maternal serum screening and nuchal translucency improves accuracy and reduces unnecessary procedures, respecting patient choice.
Area of Science:
- Perinatal medicine
- Prenatal diagnostics
- Genetics
Context:
- Historical reliance on maternal age for Down's syndrome screening is outdated.
- Advanced maternal age was a primary indication for amniocentesis due to lack of alternatives.
- Current validated methods include maternal serum screening and first-trimester nuchal translucency.
Purpose:
- To re-evaluate current Down's syndrome screening strategies.
- To advocate for integrated risk assessment over isolated factors.
- To emphasize informed patient choice in prenatal screening.
Summary:
- Sequential or independent use of screening tests significantly elevates false positives and iatrogenic fetal losses.
- Maternal age is a key risk factor for chromosomal anomalies but should be integrated into combined screening protocols.
- Serum screening currently offers better quality control than ultrasound screening.
Impact:
- Revising screening protocols can decrease iatrogenic fetal losses.
- Implementing combined screening strategies enhances detection rates for Down's syndrome.
- Informed counseling empowers women to make personalized choices regarding prenatal testing.